FDA warned NOVARX over false website claims that compounded semaglutide and tirzepatide products are FDA-approved or from FDA-approved pharmacies.
What happened
FDA identified the violations during a March 2026 review of NOVARX’s website, https://novarx.co. FDA said the site offered compounded semaglutide and tirzepatide products, labeled them with “NOVA RX” even though NOVARX is not the compounder, and claimed the products had the same active ingredient as Ozempic and came from “FDA Approved Pharmacies.” FDA said those statements falsely imply FDA approval or evaluation of the compounded drugs and the pharmacies.
What FDA found
The website’s pictured labels show “NOVA RX,” implying NOVARX made the compounded drugs when the letter says it is not the compounder.
FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)The website says compounded semaglutide offers “access to the same active ingredient found in Ozempic,” implying FDA approval or evaluation that compounded drugs do not have.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website says products are sourced from “FDA Approved Pharmacies,” but FDA does not approve or license pharmacies or outsourcing facilities or their compounded drugs.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
What FDA wants
FDA asks NOVARX to send a written response to OCQC at compoundinginspections@fda.hhs.gov within 15 business days of receiving the letter. The response should include corrective and preventive steps, documentation, the entities that produce the compounded drugs, sample labeling, and correction or removal of the false website claims.
Who should pay attention
- telehealth and online pharmacy sites selling compounded drugs
- compounders whose products are marketed by third-party websites
- clinics and brands advertising compounded semaglutide or tirzepatide
This is a summary. Read the original letter on fda.gov.